TRDX and Genesis to Pursue Objectives Separately

   SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX)

After a very careful, extensive and exhaustive search for capital in order to fund the Genesis Sub-license, TRDX board and management have reached the unfortunate conclusion that such capital for early stage biotech is in short supply. It is the opinion of both management teams that is in the best interest of both TRDX and Genesis that each party pursue its objectives on a separate course and therefore have entered into a mutual release agreement. TRDX management is still firmly of the belief that Genesis' technology is quite leading edge and that under different market conditions would have been more successful in meeting its financing obligations.

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent (www.scimedenthealth.com) is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc. www.scimedenthealth.com [e-mail] 1-866-383-1374